Vaccine for Parkinson’s Reports Positive Results from Boost Study

Monday, 12 September 2016

New study results from Austrian biotech AFFiRiS support continued development of its vaccine against the key Parkinson’s protein alpha-synuclein. Today the company announced its “boost” follow-up study — funded with a $1.04 million grant from The Michael J. Fox Foundation…

Parkinson's research

Another Leap Forward for LRRK2 Development

Monday, 29 August 2016

Denali Therapeutics — a San Francisco biotech that launched last year focused on neurodegenerative diseases including Parkinson’s — recently announced it has licensed LRRK2 inhibitor compounds from Genentech. These drug candidates may address the dysfunction seen with LRRK2 mutations, the greatest…

Another Piece of the Alpha-synuclein Puzzle Revealed

Monday, 25 July 2016

Research on alpha-synuclein, a lead target for therapy to slow or stop Parkinson’s and potential marker of disease progression, is quickly advancing, and scientists are learning more about this protein’s role in Parkinson’s disease (PD). Recently, researchers discovered how this…

Researchers Looking to Improve Diagnosis of Parkinson’s

Thursday, 14 April 2016

No objective measurement — or biomarker — currently exists to diagnose Parkinson’s disease (PD). Instead, doctors must rely on a person’s medical history and physical examination to recognize the disease. This can sometimes result in missed or incorrect diagnoses, so significant…

Fourth new research project announced in four weeks

Thursday, 7 April 2016

Shake It Up and The Michael J. Fox Foundation are on a roll! Today we share with you our commitment to fund another world class Australian research project – the fourth such announcement in four weeks! It comes less than…

Michael J. Fox, Henrik Lundqvist Talk Parkinson’s Disease

Monday, 13 April 2015

Michael J. Fox appeared on The Mask, hosted by New York Rangers goalie Henrik Lundqvist, on March 21. In addition to hockey, the two talked about Michael’s work with the Michael J. Fox Foundation and his journey since being diagnosed with Parkinson’s….

Alzheimer’s Drug Shows Promise in Slowing Disease

Monday, 30 March 2015

Michael J. Fox Foundation CEO recently shared news from pharmaceutical company Biogen Idec(renamed today as simply Biogen) around an Alzheimer’s drug in development with strong implications for Parkinson’s research. The drug — aducanumab (BIIB037) — showed safety and positive impact not…